Novavax vs Sinovac Biotech
Novavax is the larger business, with $1.12bn of revenue in fiscal 2025 against $386m for Sinovac Biotech (2.9 times as much). Novavax grew faster (64.7% against 6.8%). Novavax kept more of each dollar of sales as profit: a net margin of 39.2% against -15.5%.
| Latest fiscal year | NovavaxNVAX, 2025 | Sinovac BiotechSVA, 2025 |
|---|---|---|
| Revenue | $1.12bn | $386m |
| Revenue growth | 64.7% | 6.8% |
| Net income | $440m | −$59.7m |
| Operating margin | 40.3% | -127.0% |
| Net margin | 39.2% | -15.5% |
| Return on equity | — | -0.9% |
| Free cash flow | −$250m | −$561m |
| Cash | $241m | $488m |
| Total debt | $244m | $495m |
| Debt to equity | — | 11.1% |
| Dividend per share | — | — |
| Dividend yield | — | 760.2% |
| Share buybacks | — | — |
| Employees | 749 | — |
| Market value | $1.58bn | $465m |
| Price vs our value range | — | — |
| Moat score | 19 (Weak) | — |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 0 sales |